Lilly announces first Phase 1 data for sofetabart mipitecan in platinum-sensitive ovarian cancer
LLY•Lilly will present initial Phase 1 findings for sofetabart mipitecan with bevacizumab in platinum-sensitive ovarian cancer at the ESMO Congress in Madrid on October 23-27, 2026; the findings support its ongoing Phase 3 trial.
1. Ovarian cancer findings
Lilly will present initial Phase 1 findings for sofetabart mipitecan with bevacizumab in platinum-sensitive ovarian cancer at the ESMO Congress in Madrid, scheduled for October 23-27, 2026. The findings support the ongoing Phase 3 trial.
2. Other studies at ESMO
Lilly also plans to present updated findings on olomorasib in KRAS G12C-mutant lung cancer and selpercatinib in advanced RET-mutant medullary thyroid cancer, as well as Phase 3 postMONARCH survival data in advanced breast cancer.
